Engaging with industry
In addition to the Industry Programme, EMBL-EBI addresses the needs of industry in a number of ways. Through our participation in the Innovative Medicines Initiative (IMI), we lead projects ranging from drug safety databases to semantic enrichment of scientific literature. We support small and medium-sized enterprise (SMEs) by providing essential data infrastructure and services, enable bioinformatics spin-outs from EMBL and facilitate key pre-competitive and translational projects with our industry partners.
We welcome industry to engage with ELIXIR, the emerging pan-European infrastructure for biological information. Working together, we can empower research and the translation of discoveries into advances in medicine, health, and agriculture for the benefit of society.
The EMBL-EBI Industry Programme
Kazuhisa Tsunoyama and Hiroki Shirai, Astellas Pharma, Inc.
Since 1996 our Industry Programme has been helping industry make the most of advances in bioinformatics and cheminformatics. The strategic focus of our programme is the development of resources and services that will benefit both our members as well as our wider stakeholder communities. To that end, our members lend their insights and expertise defining and shaping the services we provide.
Our members meet regularly in different locations to discuss shared challenges and explore opportunities for precompetitive collaboration. They also identify topics for bioinformatics training workshops, which serve to facilitate the discovery of new therapeutics, vaccines, consumer products and a growing range of agricultural products.
EMBL-EBI utilises small-scale industrial collaborations as proving grounds for the adaptation of our services to directly accommodate the specific needs of our partners. We are seeking to build on these industrial partnerships to offer new adaptations to industry, without diluting our public service offering.
The Industry Programme is member-funded, and priorities are set by its members.